NAV12/06/2024 Chg.+4.1899 Type de rendement Focus sur l'investissement Société de fonds
1,130.2300USD +0.37% reinvestment Equity Worldwide Fuchs Asset M. 

Stratégie d'investissement

The main objective of the Fund is to seek to maximise total return. The Fund invests globally with at least 85% of its total assets in the equity securities of companies whose predominant economic activity is in the pharmaceuticals, biotechnology and life science sectors. The overall investment strategy of the BlueBox Precision Medicine Fund is to seek out companies that will create value for the Shareholders from precision medicine: the multi-year trend of increasingly precise and targeted drug development in the pharmaceutical and biotechnology industries. The BlueBox Precision Medicine Fund will typically hold 25 to 45 positions. The holding periods are expected to be generally long (multiple years) and turnover low, although at times the BlueBox Precision Medicine Fund may utilise shorter holding periods if value is realised more quickly or unexpected events occur.
 

Objectif d'investissement

The main objective of the Fund is to seek to maximise total return.
 

Opérations

Type de rendement: reinvestment
Fonds Catégorie: Equity
Région de placement: Worldwide
Branche: Sector Health / Pharma
Benchmark: -
Début de l'exercice: 01/01
Dernière distribution: -
Banque dépositaire: Northern Trust Global Services SE
Domicile: Luxembourg
Permission de distribution: Germany, Switzerland
Gestionnaire du fonds: Mark Dainty
Actif net: 15.86 Mio.  USD
Date de lancement: 14/06/2023
Focus de l'investissement: -

Conditions

Surtaxe d'émission: 5.00%
Frais d'administration max.: 1.50%
Investissement minimum: 10,000.00 USD
Deposit fees: -
Frais de rachat: 0.00%
Prospectus simplifié: -
 

Société de fonds

Société de fonds: Fuchs Asset M.
Adresse: 49,boulevard Prince Henri, 1724, Luxembourg
Pays: Luxembourg
Internet: info@fuchsgroup.com
 

Actifs

Stocks
 
98.20%
Cash and Other Assets
 
1.80%

Pays

United States of America
 
72.40%
United Kingdom
 
6.00%
Belgium
 
5.90%
France
 
5.30%
Switzerland
 
3.10%
Italy
 
3.00%
Denmark
 
2.50%
Autres
 
1.80%

Branches

Pharma/Biotechnology
 
64.90%
Pharma, production
 
3.00%
Cash / other assets
 
1.80%
Autres
 
30.30%